Clinical and Mechanistic Overview
Radiopharmaceuticals（放射性药物）have transitioned from niche diagnostic tools to mainstream oncology therapeutics. The theranostic（诊疗一体化）paradigm—pairing a diagnostically labeled ligand for imaging with a therapeutically labeled counterpart for treatment—now underpins regulatory approvals across neuroendocrine tumors and prostate cancer, with active expansion into a broad spectrum of solid malignancies 8.
The foundational principle is straightforward: a targeting vector (small molecule, peptide, or antibody) is conjugated to a chelator and radiolabeled with an appropriate isotope. Diagnostic isotopes emit positrons or gamma rays to enable PET or SPECT imaging; therapeutic isotopes emit alpha or beta particles to deliver cytotoxic radiation within or adjacent to tumor cells. Patient selection hinges on confirming target expression via a companion imaging agent before committing to therapy—a requirement that distinguishes radiopharmaceutical therapy from conventional systemic treatments and imposes specific infrastructure demands 2.
Personalized dosimetry is increasingly recognized as essential. Fixed-activity dosing, borrowed from early radioiodine practice, does not account for individual pharmacokinetics or the absorbed dose delivered to tumors and organs at risk. European regulatory and academic initiatives are now actively pursuing dosimetry-guided treatment planning as a standard component of radiopharmaceutical therapy cycles, with post-therapy imaging serving as a practical entry point 15.
Key Oncology Targets and Clinical Applications
Two targets have achieved regulatory approval and form the clinical anchor of the field.
Somatostatin receptors (SSTR): Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTATATE (Lutathera) received FDA approval in 2018 for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The NETTER-1 phase III trial established median overall survival of 48 months versus 36.3 months in controls, with grade ≥3 treatment-related toxicity in only 6% of patients 1. Real-world cohorts have confirmed median OS exceeding 72 months with four cycles of approximately 8 GBq each. Retreatment protocols remain feasible, with meta-analyses of 13 studies showing disease control rates near 70% and acceptable toxicity 1. The NETTER-2 trial is evaluating first-line PRRT in high-grade G2/G3 neuroendocrine tumors (NETs), with preliminary data showing median progression-free survival (PFS) of 22.8 months versus 8.5 months for high-dose octreotide 1.
PSMA (prostate-specific membrane antigen): [177Lu]Lu-PSMA-617 (Pluvicto; Novartis) was first approved by the FDA in March 2022 for post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC). In March 2025, an expanded indication was granted for pre-chemotherapy use, based on the PSMAfore trial demonstrating radiographic PFS of 11.6 months versus 5.6 months with androgen receptor pathway inhibitor (ARPI) switching (hazard ratio 0.41) 2044. This expansion could triple the eligible patient population. Paired PSMA-PET imaging agents ([68Ga]Ga-PSMA-11, 18F-DCFPyL/Pylarify) are now standard-of-care for staging and biochemical recurrence detection 1244.
Emerging targets are advancing through clinical and preclinical pipelines:
Fibroblast activation protein (FAP): FAP-alpha is a membrane-bound serine protease overexpressed in cancer-associated fibroblasts (CAFs) across diverse solid tumors, including pancreatic, colorectal, breast, and ovarian cancers. A 2025 systematic review of 27 studies (144 patients) reported disease control rates of 18–83% with [177Lu]Lu-FAPI, with rare grade 3–4 toxicity 24. Diagnostic [68Ga]Ga-FAP-2286 demonstrated higher SUVmax than [18F]FDG across multiple cancer types in a 46-patient study, with particularly superior performance in sarcoma, cholangiocarcinoma, and breast cancer 36. Preclinical work demonstrates that dimeric FAP ligands combined with PD-L1 checkpoint inhibitors achieve complete tumor elimination in mouse models, pointing to immunotherapy synergy as a key future direction 26.
Radium-223 (bone-targeted alpha therapy): The PEACE-3 trial, presented at ESMO 2024, showed that radium-223 (Xofigo; Bayer) combined with enzalutamide improved radiographic PFS to 19.4 months versus 16.4 months (HR 0.69; P = 0.0009) with a 31% reduction in death risk in mCRPC patients with bone metastases 20.
Table 1. Key Oncology Radiopharmaceutical Targets
| Target | Main Tumor Types | Representative Agents | Development/Approval Status | Clinical Value | Key Limitations |
|---|---|---|---|---|---|
| SSTR2 | GEP-NETs, carcinoid | [177Lu]Lu-DOTATATE (Lutathera); [177Lu]Lu-edotreotide (ITM-11); [225Ac]Ac-DOTATATE (RYZ101) | Lutathera: FDA/EMA approved; ITM-11: Phase III; RYZ101: Phase III | Durable responses; OS benefit; retreatment feasible | Hematologic toxicity; renal dose limits; variable SSTR expression |
| PSMA | mCRPC; biochemical recurrence | Pluvicto ([177Lu]Lu-PSMA-617); [68Ga]Ga-PSMA-11; 18F-DCFPyL; [225Ac]Ac-PSMA-617 | Pluvicto: FDA approved (2022, expanded 2025); imaging: FDA approved; alpha-emitters: Phase I/II | Superior imaging vs. conventional; OS benefit in mCRPC; earlier-disease trials ongoing | PSMA-negative disease; neuroendocrine shift; salivary/renal toxicity |
| FAP-alpha | Pancreatic, colorectal, breast, ovarian, sarcoma | [68Ga]Ga-FAPI, [68Ga]Ga-FAP-2286; [177Lu]Lu-FAPI; [225Ac]Ac-FAP-2286 | Diagnostic: EMA approval pending; therapeutic: Phase II | Broad tumor expression; superior FDG contrast; immunotherapy synergy potential | Heterogeneous FAP expression; limited RCT data; manufacturing scale |
| Bone metastases (calcium-mimetic) | mCRPC with bone metastases | Radium-223 dichloride (Xofigo) | FDA approved (2013); PEACE-3 validated combination | OS benefit; alpha-emitter precision; bone-specific | Restricted to bone disease; visceral metastases excluded |
| HER2 | Breast, gastric cancer | [89Zr]Zr-trastuzumab; [177Lu]Lu-RAD-202 | Phase I/II (preclinical for 177Lu) | Non-invasive HER2 assessment; theranostic potential | Slow antibody kinetics; competition from ADCs; early stage |
| GRPR | Prostate cancer | [68Ga]Ga-GRPR ligands; heterodimeric constructs | Clinical trials (early phase) | Complementary to PSMA in PSMA-negative disease | Limited therapeutic data; small patient populations |
Isotopes and Modality Selection
Table 2. Diagnostic and Therapeutic Isotopes
| Isotope | Emission / Type | Approximate Half-life | Main Use | Advantages | Constraints |
|---|---|---|---|---|---|
| 18F (Fluorine-18) | β+ (PET) | 110 min | FDG, PSMA, FAPI imaging | Longer half-life enables regional distribution; high resolution | Cyclotron required; limited to imaging; dose accumulation |
| 68Ga (Gallium-68) | β+ (PET) | 68 min | SSTR, PSMA, FAPI imaging | Generator-produced; no cyclotron needed; rapid synthesis | Very short half-life limits distribution radius; generator monitoring required |
| 64Cu (Copper-64) | β+/β− | 12.7 h | Antibody and peptide imaging | Longer half-life for slow-targeting antibodies; theranostic potential | Cyclotron required; less established than 68Ga; limited availability |
| 89Zr (Zirconium-89) | β+ (PET) | 78.4 h | Antibody immuno-PET (e.g., HER2) | Long half-life matches antibody kinetics | Cyclotron required; high positron energy reduces resolution; bone signal |
| 177Lu (Lutetium-177) | β− | 6.7 days | PSMA-617, DOTATATE, FAPI therapy | Proven supply; manageable toxicity; paired with 68Ga diagnostics | Off-target salivary gland/bone marrow uptake; cumulative renal dose |
| 225Ac (Actinium-225) | α | 10 days | PSMA, SSTR, FAP (investigational) | High LET; potent DNA double-strand breaks; short tissue range (~50 µm) | Severely limited supply; high cost; salivary toxicity (>60%); scaling unresolved |
| 223Ra (Radium-223) | α | 11.4 days | Bone-targeted therapy (mCRPC) | FDA approved; mimics calcium; favorable OS data | Bone-specific only; not for soft-tissue disease |
| 212Pb (Lead-212) | β− (α from daughter nuclides) | 10.6 h | PSMA, SSTR (preclinical/early clinical) | Generator-produced; shorter half-life than 225Ac; favorable for peptide agents | Early data; limited manufacturing capacity; regulatory pathway evolving |
| 131I (Iodine-131) | β−/γ | 8.0 days | Thyroid cancer; MIBG; FAP mAb | Longstanding clinical use; established logistics | Off-target radiation exposure; requires iodine-blocking; thyroid dose |
| 161Tb (Terbium-161) | β−/Auger | 6.9 days | PSMA, SSTR (VIOLET trial) | Auger electrons enhance nucleus-targeted dose vs. 177Lu; similar chemistry | Emerging supply; limited long-term toxicity data; nascent regulatory pathway |
FDG = fluorodeoxyglucose; LET = linear energy transfer; mCRPC = metastatic castration-resistant prostate cancer; MIBG = meta-iodobenzylguanidine
Alpha-emitters offer substantially higher LET than beta-emitters, delivering more cytotoxic radiation per cell traversal while minimizing dose to surrounding normal tissue—a property that makes them particularly attractive for diffuse micrometastatic disease and for patients who have progressed after beta-emitter therapy 611. Preclinical data for [177Lu]Lu-PSMA-NARI-56, incorporating an albumin-binding moiety, showed 98% tumor inhibition at day 58 versus 58% for standard [177Lu]Lu-PSMA-617 in xenograft models, illustrating active ligand optimization strategies 13.
Manufacturing, Logistics, and Operational Bottlenecks
Table 3. Manufacturing and Supply-Chain Considerations
| Step / Constraint | Key Issue | Clinical or Commercial Impact | Mitigation Strategies |
|---|---|---|---|
| Lutetium-177 production | Reactor neutron irradiation of 176Yb targets; 2024–2025 reactor outages caused supply rationing | Treatment delays; forced rationing at radiopharmacies | Carrier-added vs. no-carrier-added synthesis diversification; expanded reactor capacity; decentralized radiopharmacy networks |
| Actinium-225 production | Relies on thorium-229 decay or accelerator routes; extremely limited global capacity | Bottleneck for all alpha-emitter clinical programs; constrains trial enrollment | TerraPower $450M Philadelphia facility (2029 target); DOE isotope network; accelerator-based production scale-up |
| Cyclotron infrastructure | ~1,550 medical cyclotrons globally; ~800 in Asia (320 China), ~335 North America, ~320 Europe; only ~140 large-capacity units | Geographic access disparities; short-half-life agents cannot reach underserved regions | Regional cyclotron investment; generator-based production for remote areas; drone/fast-courier logistics 25 |
| Research reactor capacity | 222 research reactors globally; 30 with industrial production capacity; 5 new large reactors under construction, none operational before 2032 | Ongoing supply fragility for reactor-produced isotopes | NorthStar Mo-99 cyclotron production; advance purchase agreements; international supply-chain diversification 25 |
| Radiochemistry workforce | Estimated shortage of ~300 trained radiochemists in Europe alone | New-agent development bottleneck; geographic distribution limits | Automated synthesis modules; academic-industry training partnerships; regulatory harmonization of kit-based labeling |
| Cold-chain and logistics | Short half-lives require rapid QC, dispatch, and administration; fragmented EU radiation-safety regulations | Higher per-dose costs; rural and Eastern European underservice | EU regulatory streamlining (Q1 2026 initiatives); centralized hub-and-spoke distribution; on-site generator elution systems |
| Hospital readiness | Hot-cell infrastructure, PET/CT/SPECT availability, radiation safety licensing variability | Uneven clinical adoption; quality disparities | Novartis $23B U.S. manufacturing expansion (5 facilities by 2028); CMS Medicare reimbursement incentives; SNMMI/ASTRO workforce programs 2045 |
| Reimbursement | MUC-based pricing for U.S. diagnostics; variable EU national policies; 340B offsets | Pricing uncertainty; delayed hospital uptake | CMS 2026 OPPS-ASC rule: $10 add-on for domestically produced Tc-99m; EU harmonization under national cancer plans; Germany established nationwide 177Lu-PSMA reimbursement (2023) 4748 |
AI-driven dosimetry represents a cross-cutting solution: machine learning tools can automate organ and tumor segmentation from post-therapy SPECT/CT images, reducing the time burden of personalized dosimetry calculations and enabling routine clinical implementation without requiring dedicated physics support for every patient 45.
Market and Competitive Landscape
Table 4. Market and Competitive Landscape
| Segment / Product Class | Representative Companies / Products | Current Status (2026) | Growth Drivers | Key Risks |
|---|---|---|---|---|
| PSMA-targeted therapy (177Lu) | Novartis (Pluvicto); Eli Lilly/POINT (PNT-2002); Curium (177Lu-PSMA-I&T) | Pluvicto FDA-approved (expanded March 2025); PNT-2002 Phase III; Pluvicto projected $1B+ revenue 2026 | Earlier disease indication; PSMAfore data; combination trials (ENZA-p, LuPARP) | Resistance/PSMA loss; treatment sequencing complexity; long-term MDS risk (~1.3%) |
| SSTR-targeted therapy (177Lu) | Novartis (Lutathera); ITM Oncologics (ITM-11/177Lu-edotreotide); BMS/RayzeBio (RYZ101); Jiangsu Hengrui (China) | Lutathera approved (US/EU); pediatric approval 2024; ITM-11 Phase III; RYZ101 Phase III; China 177Lu-octreotide Phase III | First-line NETTER-2 positioning; pediatric expansion; geographic growth (China) | Kidney/bone marrow toxicity; SSTR heterogeneity; manufacturing capacity 19 |
| Alpha-emitter therapies | Novartis (225Ac-PSMA-617); ARTBIO/Bayer (212Pb-PSMA); BMS (RYZ101/225Ac-DOTATATE) | Phase I/II (PSMA/SSTR alpha); PEACE-3 validates 223Ra combination | Post-Lu progression; high LET efficacy; emerging isotope supply | Supply constraints; salivary toxicity; long-term safety data immature |
| FAP theranostics | Novartis (AAA-614: 68Ga/177Lu/225Ac-FAP-2286); Boehringer Ingelheim (131I-BIBH-1) | Preclinical to Phase II; EMA diagnostic approval pending | Broad tumor expression; PD-L1 synergy; cross-tumor applicability | Limited RCT data; heterogeneous FAP expression; manufacturing scale 2428 |
| PSMA imaging diagnostics | Lantheus (Pylarify/18F-DCFPyL); Telix (Illuccix/68Ga-PSMA-11); other agents approved by NMPA (2025) | FDA/EMA approved; Illuccix NDA accepted by NMPA (Jan 2026); approval pending; 94.8% positive predictive value in Chinese Phase 3 | BCR staging replacing conventional imaging; AI-assisted quantification | Reimbursement parity; competition from emerging ligands 22 |
| M&A / business development | Novartis (Mariana Oncology, $1.75B); BMS (RayzeBio, $4.1B); Eli Lilly (POINT Biopharma, $1.4B); AstraZeneca (Fusion, $2B); Lantheus (Evergreen, $1B) | Completed acquisitions consolidating pipeline depth | Platform value; alpha-emitter pipeline; geographic expansion | Integration risk; clinical attrition; supply-chain unresolved |
The global radiopharmaceutical market was valued at approximately $9.07 billion in 2023 and is projected to reach $26.51 billion by 2031 20. The European segment alone was valued at $2.33 billion in 2025, with a projected CAGR of 11.4% to 2034 46. China's accelerated infrastructure investment—1,600+ PET/CT cameras by end of 2025 versus only 133 in 2010—positions it as a critical growth market 22.
Clinical Adoption and Future Directions
Several evidence gaps remain critical. Response assessment in NETs is hampered by the inadequacy of conventional RECIST 1.1 criteria for slow-growing tumors; composite evaluation using somatostatin receptor (SST) PET/CT and FDG PET/CT is recommended but unstandardized. Baseline receptor tumor volume (RTV) ≥7.0 mL independently predicts disease progression (HR 3.0, P = 0.04), while FDG-positivity outperforms histologic grading for risk stratification in G1/G2 NET patients 117.
Combination strategies are an active frontier. Radiosensitizing chemotherapy sandwiched between PRRT cycles (capecitabine, CAPTEM) demonstrated 72.5% PFS and 80.4% OS rates at 36 months in a 38-patient pancreatic NET cohort 1. PARP inhibitors, anti-angiogenic agents, and PD-1/PD-L1 checkpoint inhibitors are under evaluation with both 177Lu-DOTATATE and 177Lu-PSMA-617. In FAP-targeted therapy, preclinical evidence that 177Lu-DOTA-2P(FAPI)2 upregulates PD-L1 and that the combination with anti-PD-L1 eliminates tumors with 100% rejection on rechallenge provides compelling rationale for clinical trials 26.
Intra-arterial administration of PSMA-targeted agents for brain tumors represents an emerging interventional approach, with proof-of-concept data showing higher tumor absorbed doses compared with intravenous delivery 16. Dosimetry standardization, regulatory harmonization across the FDA, EMA, and China's NMPA, and equitable access—particularly for alpha-emitters whose supply currently restricts enrollment even in well-funded trial programs—are the defining challenges for the field through 2030 15725.
In summary, oncology radiopharmaceuticals in 2026 represent a rapidly maturing class of precision medicines with established survival benefits in NET and prostate cancer, a diversified and well-capitalized development pipeline, and growing clinical relevance across FAP-positive solid tumors. Realizing this potential at scale requires parallel investment in isotope production infrastructure, healthcare system readiness, and dosimetry-guided personalization frameworks.